Momoko Ishikawa

Company: VLP Therapeutics

Job title: Scientist I

Seminars:

Myeloid Cell Targeting Cancer Immunotherapy via Localized Gene Delivery with Alphavirus Replicon Particles (VRP) Expressing IL-12 3:30 pm

VRP containing a saRNA vector were developed to reprogram the immunosuppressive tumor microenvironment in solid tumors. In preclinical studies, intratumoral injection of VRP efficiently delivered saRNA expressing IL-12, reduced immunosuppressive cell populations, and increased antigenspecific T cells. The safety and efficacy of VLPONC-01 will be assessed in a phase I trial as a neoadjuvant treatment…Read more

day: Conference Day Two